The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis (original) (raw)

2007, Journal of Experimental Medicine

AI-generated Abstract

Tumor immunologists aim to stimulate anticancer responses through the immune system, focusing mostly on the adaptive response. The role of nonlymphocytic immune cells in tumor eradication is increasingly recognized. Vascular disrupting agents (VDAs) like DMXAA have shown potential in treating multiple cancers by collapsing tumor vasculature. This study identifies DMXAA as a potent activator of the TBK1-IRF-3 signaling pathway, resulting in significant interferon beta (IFN-β) production specifically in macrophages, independent of traditional TLR and MAPK pathways. These findings enhance understanding of VDA mechanisms and could inform future cancer therapies.